|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FZD10 |
Gene summary for FZD10 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FZD10 | Gene ID | 11211 |
| Gene name | frizzled class receptor 10 | |
| Gene Alias | CD350 | |
| Cytomap | 12q24.33 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | Q6NSL8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 11211 | FZD10 | P2T-E | Human | Esophagus | ESCC | 3.34e-54 | 9.47e-01 | 0.1177 |
| 11211 | FZD10 | P4T-E | Human | Esophagus | ESCC | 2.22e-13 | 4.26e-01 | 0.1323 |
| 11211 | FZD10 | P9T-E | Human | Esophagus | ESCC | 1.30e-07 | 1.38e-01 | 0.1131 |
| 11211 | FZD10 | P10T-E | Human | Esophagus | ESCC | 2.47e-06 | 9.55e-02 | 0.116 |
| 11211 | FZD10 | P12T-E | Human | Esophagus | ESCC | 1.25e-06 | 3.29e-02 | 0.1122 |
| 11211 | FZD10 | P15T-E | Human | Esophagus | ESCC | 9.88e-14 | 4.18e-01 | 0.1149 |
| 11211 | FZD10 | P16T-E | Human | Esophagus | ESCC | 1.85e-03 | 2.25e-02 | 0.1153 |
| 11211 | FZD10 | P22T-E | Human | Esophagus | ESCC | 1.63e-14 | 7.97e-02 | 0.1236 |
| 11211 | FZD10 | P23T-E | Human | Esophagus | ESCC | 1.40e-03 | 5.18e-02 | 0.108 |
| 11211 | FZD10 | P26T-E | Human | Esophagus | ESCC | 2.54e-07 | 1.41e-01 | 0.1276 |
| 11211 | FZD10 | P27T-E | Human | Esophagus | ESCC | 2.79e-15 | 3.30e-01 | 0.1055 |
| 11211 | FZD10 | P28T-E | Human | Esophagus | ESCC | 1.33e-12 | 3.04e-01 | 0.1149 |
| 11211 | FZD10 | P30T-E | Human | Esophagus | ESCC | 1.73e-09 | 5.46e-01 | 0.137 |
| 11211 | FZD10 | P31T-E | Human | Esophagus | ESCC | 9.78e-14 | 2.30e-01 | 0.1251 |
| 11211 | FZD10 | P36T-E | Human | Esophagus | ESCC | 1.71e-02 | 1.64e-01 | 0.1187 |
| 11211 | FZD10 | P37T-E | Human | Esophagus | ESCC | 2.87e-07 | 4.02e-01 | 0.1371 |
| 11211 | FZD10 | P39T-E | Human | Esophagus | ESCC | 5.64e-11 | 1.45e-01 | 0.0894 |
| 11211 | FZD10 | P42T-E | Human | Esophagus | ESCC | 5.12e-06 | 1.99e-01 | 0.1175 |
| 11211 | FZD10 | P47T-E | Human | Esophagus | ESCC | 1.39e-10 | 2.34e-01 | 0.1067 |
| 11211 | FZD10 | P48T-E | Human | Esophagus | ESCC | 6.97e-08 | 1.87e-01 | 0.0959 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:007190016 | Esophagus | ESCC | regulation of protein serine/threonine kinase activity | 227/8552 | 359/18723 | 1.12e-11 | 4.10e-10 | 227 |
| GO:001605517 | Esophagus | ESCC | Wnt signaling pathway | 268/8552 | 444/18723 | 2.32e-10 | 6.58e-09 | 268 |
| GO:019873817 | Esophagus | ESCC | cell-cell signaling by wnt | 269/8552 | 446/18723 | 2.41e-10 | 6.79e-09 | 269 |
| GO:0032970111 | Esophagus | ESCC | regulation of actin filament-based process | 231/8552 | 397/18723 | 2.91e-07 | 4.20e-06 | 231 |
| GO:0032956111 | Esophagus | ESCC | regulation of actin cytoskeleton organization | 210/8552 | 358/18723 | 4.40e-07 | 6.00e-06 | 210 |
| GO:006007016 | Esophagus | ESCC | canonical Wnt signaling pathway | 180/8552 | 303/18723 | 9.15e-07 | 1.17e-05 | 180 |
| GO:00719029 | Esophagus | ESCC | positive regulation of protein serine/threonine kinase activity | 124/8552 | 200/18723 | 2.27e-06 | 2.61e-05 | 124 |
| GO:004586018 | Esophagus | ESCC | positive regulation of protein kinase activity | 219/8552 | 386/18723 | 6.91e-06 | 6.97e-05 | 219 |
| GO:003367420 | Esophagus | ESCC | positive regulation of kinase activity | 260/8552 | 467/18723 | 7.26e-06 | 7.22e-05 | 260 |
| GO:0051346110 | Esophagus | ESCC | negative regulation of hydrolase activity | 208/8552 | 379/18723 | 1.76e-04 | 1.14e-03 | 208 |
| GO:00434055 | Esophagus | ESCC | regulation of MAP kinase activity | 102/8552 | 177/18723 | 8.89e-04 | 4.55e-03 | 102 |
| GO:00355671 | Esophagus | ESCC | non-canonical Wnt signaling pathway | 45/8552 | 72/18723 | 2.97e-03 | 1.24e-02 | 45 |
| GO:00325261 | Esophagus | ESCC | response to retinoic acid | 63/8552 | 107/18723 | 4.05e-03 | 1.62e-02 | 63 |
| GO:004308715 | Esophagus | ESCC | regulation of GTPase activity | 183/8552 | 348/18723 | 5.34e-03 | 2.00e-02 | 183 |
| GO:019873821 | Liver | HCC | cell-cell signaling by wnt | 247/7958 | 446/18723 | 2.11e-08 | 4.96e-07 | 247 |
| GO:001605521 | Liver | HCC | Wnt signaling pathway | 245/7958 | 444/18723 | 3.68e-08 | 8.09e-07 | 245 |
| GO:003297022 | Liver | HCC | regulation of actin filament-based process | 222/7958 | 397/18723 | 3.81e-08 | 8.30e-07 | 222 |
| GO:003295622 | Liver | HCC | regulation of actin cytoskeleton organization | 202/7958 | 358/18723 | 6.18e-08 | 1.29e-06 | 202 |
| GO:007190021 | Liver | HCC | regulation of protein serine/threonine kinase activity | 189/7958 | 359/18723 | 5.97e-05 | 5.47e-04 | 189 |
| GO:006007021 | Liver | HCC | canonical Wnt signaling pathway | 162/7958 | 303/18723 | 7.00e-05 | 6.32e-04 | 162 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa05022210 | Esophagus | ESCC | Pathways of neurodegeneration - multiple diseases | 318/4205 | 476/8465 | 6.10e-15 | 2.04e-13 | 1.05e-13 | 318 |
| hsa05010210 | Esophagus | ESCC | Alzheimer disease | 263/4205 | 384/8465 | 1.80e-14 | 5.47e-13 | 2.80e-13 | 263 |
| hsa0516510 | Esophagus | ESCC | Human papillomavirus infection | 215/4205 | 331/8465 | 7.86e-09 | 7.12e-08 | 3.65e-08 | 215 |
| hsa0520529 | Esophagus | ESCC | Proteoglycans in cancer | 138/4205 | 205/8465 | 1.79e-07 | 1.40e-06 | 7.15e-07 | 138 |
| hsa0522518 | Esophagus | ESCC | Hepatocellular carcinoma | 109/4205 | 168/8465 | 4.27e-05 | 1.88e-04 | 9.64e-05 | 109 |
| hsa041505 | Esophagus | ESCC | mTOR signaling pathway | 98/4205 | 156/8465 | 5.81e-04 | 1.95e-03 | 9.97e-04 | 98 |
| hsa0439018 | Esophagus | ESCC | Hippo signaling pathway | 92/4205 | 157/8465 | 1.46e-02 | 3.31e-02 | 1.69e-02 | 92 |
| hsa0502238 | Esophagus | ESCC | Pathways of neurodegeneration - multiple diseases | 318/4205 | 476/8465 | 6.10e-15 | 2.04e-13 | 1.05e-13 | 318 |
| hsa0501038 | Esophagus | ESCC | Alzheimer disease | 263/4205 | 384/8465 | 1.80e-14 | 5.47e-13 | 2.80e-13 | 263 |
| hsa0516515 | Esophagus | ESCC | Human papillomavirus infection | 215/4205 | 331/8465 | 7.86e-09 | 7.12e-08 | 3.65e-08 | 215 |
| hsa0520537 | Esophagus | ESCC | Proteoglycans in cancer | 138/4205 | 205/8465 | 1.79e-07 | 1.40e-06 | 7.15e-07 | 138 |
| hsa0522519 | Esophagus | ESCC | Hepatocellular carcinoma | 109/4205 | 168/8465 | 4.27e-05 | 1.88e-04 | 9.64e-05 | 109 |
| hsa0415013 | Esophagus | ESCC | mTOR signaling pathway | 98/4205 | 156/8465 | 5.81e-04 | 1.95e-03 | 9.97e-04 | 98 |
| hsa0439019 | Esophagus | ESCC | Hippo signaling pathway | 92/4205 | 157/8465 | 1.46e-02 | 3.31e-02 | 1.69e-02 | 92 |
| hsa0501022 | Liver | HCC | Alzheimer disease | 254/4020 | 384/8465 | 3.75e-14 | 8.97e-13 | 4.99e-13 | 254 |
| hsa0502222 | Liver | HCC | Pathways of neurodegeneration - multiple diseases | 298/4020 | 476/8465 | 6.59e-12 | 1.30e-10 | 7.22e-11 | 298 |
| hsa052258 | Liver | HCC | Hepatocellular carcinoma | 106/4020 | 168/8465 | 2.87e-05 | 1.85e-04 | 1.03e-04 | 106 |
| hsa051652 | Liver | HCC | Human papillomavirus infection | 188/4020 | 331/8465 | 3.34e-04 | 1.49e-03 | 8.29e-04 | 188 |
| hsa041502 | Liver | HCC | mTOR signaling pathway | 95/4020 | 156/8465 | 4.70e-04 | 1.99e-03 | 1.11e-03 | 95 |
| hsa0520521 | Liver | HCC | Proteoglycans in cancer | 121/4020 | 205/8465 | 5.22e-04 | 2.18e-03 | 1.21e-03 | 121 |
| Page: 1 2 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| WNT5B | FZD10 | WNT5B_FZD10 | ncWNT | CRC | MSI-H |
| WNT5A | FZD10 | WNT5A_FZD10 | ncWNT | Esophagus | ESCC |
| WNT5B | FZD10 | WNT5B_FZD10 | ncWNT | Esophagus | ESCC |
| WNT10A | FZD10_LRP6 | WNT10A_FZD10_LRP6 | WNT | Esophagus | ESCC |
| WNT10B | FZD10_LRP6 | WNT10B_FZD10_LRP6 | WNT | Esophagus | ESCC |
| WNT2 | FZD10_LRP6 | WNT2_FZD10_LRP6 | WNT | Esophagus | ESCC |
| WNT2B | FZD10_LRP6 | WNT2B_FZD10_LRP6 | WNT | Esophagus | ESCC |
| WNT3A | FZD10_LRP6 | WNT3A_FZD10_LRP6 | WNT | Esophagus | ESCC |
| WNT7B | FZD10_LRP6 | WNT7B_FZD10_LRP6 | WNT | Esophagus | ESCC |
| WNT9A | FZD10_LRP6 | WNT9A_FZD10_LRP6 | WNT | Esophagus | ESCC |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FZD10 | SNV | Missense_Mutation | rs767950238 | c.1270N>T | p.Arg424Trp | p.R424W | Q9ULW2 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD |
| FZD10 | SNV | Missense_Mutation | c.1333N>A | p.Gly445Arg | p.G445R | Q9ULW2 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| FZD10 | SNV | Missense_Mutation | novel | c.1430N>T | p.Ala477Val | p.A477V | Q9ULW2 | protein_coding | tolerated(0.25) | benign(0.031) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| FZD10 | SNV | Missense_Mutation | novel | c.1085N>T | p.Pro362Leu | p.P362L | Q9ULW2 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C5-A7UI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| FZD10 | SNV | Missense_Mutation | c.353C>G | p.Ser118Cys | p.S118C | Q9ULW2 | protein_coding | deleterious(0.04) | probably_damaging(0.957) | TCGA-C5-A7X5-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | carboplatin | PD | |
| FZD10 | SNV | Missense_Mutation | c.865N>A | p.Ala289Thr | p.A289T | Q9ULW2 | protein_coding | deleterious(0) | probably_damaging(0.981) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| FZD10 | SNV | Missense_Mutation | novel | c.791N>C | p.Ile264Thr | p.I264T | Q9ULW2 | protein_coding | deleterious(0) | probably_damaging(0.973) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| FZD10 | SNV | Missense_Mutation | c.31N>T | p.Val11Phe | p.V11F | Q9ULW2 | protein_coding | deleterious(0.04) | benign(0.047) | TCGA-A6-2682-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5 | PD | |
| FZD10 | SNV | Missense_Mutation | c.727G>A | p.Ala243Thr | p.A243T | Q9ULW2 | protein_coding | tolerated(0.37) | benign(0.269) | TCGA-A6-4105-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| FZD10 | SNV | Missense_Mutation | c.1361C>T | p.Pro454Leu | p.P454L | Q9ULW2 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3685-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |